GSK Nears $1 Billion Deal for Biotech Company IDRx
GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...
pharmaphorum1d
Is GSK prepping a $1bn takeover bid for IDRx?
GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx
British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing ...
GSK in advanced talks to purchase U.S. biotech IDRx, FT reports
GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...
GSK’s GSK’227 receives FDA BTD for treating adults with relapsed osteosarcoma
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...
FierceBiotech1mon
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...
MM&M1mon
GSK highlights positive Blenrep data from Phase 3 trial at ASH
The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...
London South East3d
GSK hails FDA breakthrough therapy designation for bone cancer drug
(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer. The London-based ...